An open-label, prospective study of an oral polyvalent bacterial lysate (Luivac) in the treatment of recurrent respiratory tract infections in Thai patients.

@article{Jareoncharsri2003AnOP,
  title={An open-label, prospective study of an oral polyvalent bacterial lysate (Luivac) in the treatment of recurrent respiratory tract infections in Thai patients.},
  author={Perapun Jareoncharsri and Chaweewan Bunnag and Prayuth Tunsuriyawong and Paraya Assanasane and Siriporn Voraprayoon and Bangon Pinkaew},
  journal={Asian Pacific journal of allergy and immunology},
  year={2003},
  volume={21 4},
  pages={223-30}
}
An open-label, non-comparative study was performed in the Department of Otolaryngology, Siriraj Hospital, Bangkok, Thailand, to assess the safety, tolerability, acceptability and efficacy of an oral polyvalent bacterial lysate (Luivac) in the treatment of recurrent respiratory tract infections (RTIs) in Thai patients. Thirty-three patients were included in this study, 18 males and 15 females, with a mean age of 34.0 +/- 14.7 years. The mean number of RTIs during the 12-month period preceding… CONTINUE READING
2 Citations
0 References
Similar Papers

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…